Global Cancer Diagnostics Market Size- By Product, By Type, By Application, By End-User, By Test Type, By Coverage- Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Cancer Diagnostics Market Introduction and Overview

According to SPER market research, 'Global Cancer Diagnostics Market Size- By Product, By Type, By Application, By End-User, By Test Type, By Coverage- Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Cancer Diagnostics Market is predicted to reach 204.98 billion by 2034 with a CAGR of 6.43%.

Cancer diagnostics is the identification and diagnosis of cancer in the body using a range of medical tests and technology. Biopsies, advanced molecular diagnostics (genetic testing), laboratory testing (blood, urine, and tissue analysis), imaging (MRI, CT scans, X-rays), and other techniques are employed. A prompt and precise diagnosis helps define the type, location, and stage of cancer, impacting treatment decisions and improving patient outcomes.

Restraints: The market for cancer diagnostics is confronted with a number of obstacles despite its optimistic outlook. Particularly in areas with low and intermediate incomes, accessibility is restricted by the high expenses of sophisticated diagnostic tools and treatments. Complex reimbursement schemes and delayed regulatory clearances are further barriers to the use of innovative diagnostic technology.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Product, By Type, By Application, By End User, By Test Type, By Coverage

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

Abbott, BD, F. Hoffmann-La Roche Ltd, GE Healthcare, Hologic, Inc, Illumina, Inc, Koninklijke Philips N.V (Philips), QIAGEN, Siemens Healthcare GmbH, Thermo Fisher Scientific, Inc.

Global Cancer Diagnostics Market Segmentation:

By Product: Based on the Product, Global Cancer Diagnostics Market is segmented as; Consumables, Instruments, Services.

By Type: Based on the Type, Global Cancer Diagnostics Market is segmented as; IVD, LDT, Imaging.

By Application: Based on the Application, Global Cancer Diagnostics Market is segmented as; Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer, Skin Cancer, Blood Cancer, Kidney Cancer, Liver Cancer, Pancreatic Cancer, Ovarian Cancer, Others.

By End-User: Based on the End User, Global Cancer Diagnostics Market is segmented as; Hospitals, Laboratories, Others.

By Test Type: Based on the Test Type, Global Cancer Diagnostics Market is segmented as; Biopsy, Others.

By Coverage: Based on the Coverage, Global Cancer Diagnostics Market is segmented as; Public Insurance, Private Insurance.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA25195

1.Introduction

1.1.Scope of the report
1.2.Market segment analysis

2.Research Methodology

2.1.Research data source
- 2.1.1.Secondary Data
- 2.1.2.Primary Data
- 2.1.3.SPER's internal database
- 2.1.4.Premium insight from KOL's
2.2.Market size estimation
- 2.2.1.Top-down and Bottom-up approach
2.3.Data triangulation

3.Executive Summary

4.Market Dynamics

4.1.Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1.Drivers
- 4.1.2.Restraints
- 4.1.3.Opportunities
- 4.1.4.Challenges

5.Market variable and outlook

5.1.SWOT Analysis
- 5.1.1.Strengths
- 5.1.2.Weaknesses
- 5.1.3.Opportunities
- 5.1.4.Threats
5.2.PESTEL Analysis
- 5.2.1.Political Landscape
- 5.2.2.Economic Landscape
- 5.2.3.Social Landscape
- 5.2.4.Technological Landscape
- 5.2.5.Environmental Landscape
- 5.2.6.Legal Landscape
5.3.PORTERs Five Forces
- 5.3.1.Bargaining power of suppliers
- 5.3.2.Bargaining power of buyers
- 5.3.3.Threat of Substitute
- 5.3.4.Threat of new entrant
- 5.3.5.Competitive rivalry
5.4.Heat Map Analysis

6.Competitive Landscape

6.1.Global Cancer Diagnostics Market Manufacturing Base Distribution, Sales Area, Product Type
6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Cancer Diagnostics Market

7.Global Cancer Diagnostics Market, By Product (USD Million) 2021-2034

7.1.Instruments
- 7.1.1.Pathology-based Instruments
- 7.1.1.1.Slide Staining Systems
- 7.1.1.2.Tissue Processing Systems
- 7.1.1.3.Cell Processors
- 7.1.1.4.PCR Instruments
- 7.1.1.5.NGS Instruments
- 7.1.1.6.Microarrays
- 7.1.1.7.Other Pathology-based Instruments
- 7.1.2.Imaging Instruments
- 7.1.3.Others
7.2.Consumables
- 7.2.1.Antibodies
- 7.2.2.Kits & reagents
- 7.2.3.Probes
- 7.2.4.Others
7.3.Services

8.Global Cancer Diagnostics Market, By Type (USD Million) 2021-2034

8.1. IVD
- 8.1.1.By Type
- 8.1.1.1.Diagnosis
- 8.1.1.2.Early Detection
- 8.1.1.3.Therapy Selection
- 8.1.1.4.Monitoring
- 8.1.2.By Technology
- 8.1.2.1.Polymerase Chain Reaction (PCR)
- 8.1.2.2.In Situ Hybridization (ISH)
- 8.1.2.3.Immunohistochemistry (IHC)
- 8.1.2.4.Next-generation Sequencing (NGS)
- 8.1.2.5.Microarrays
- 8.1.2.6.Flow Cytometry
- 8.1.2.7.Immunoassays
- 8.1.2.8.Other IVD Testing Technologies
8.2.LDT
8.3.Imaging
- 8.3.1.Magnetic Resonance Imaging (MRI)
- 8.3.2.Computed Tomography (CT)
- 8.3.3.Positron Emission Tomography (PET)
- 8.3.4.Mammography
- 8.3.5.Ultrasound
- 8.3.6.Others

9.Global Cancer Diagnostics Market, By Application (USD Million) 2021-2034

9.1.Breast Cancer
9.2.Colorectal Cancer
9.3.Cervical Cancer
9.4.Lung Cancer
9.5.Prostate Cancer
9.6.Skin Cancer
9.7.Blood Cancer
9.8.Kidney Cancer
9.9.Liver Cancer
9.10.Pancreatic Cancer
9.11.Ovarian Cancer
9.12.Others

10.Global Cancer Diagnostics Market, By End User (USD Million) 2021-2034

10.1.Hospitals
10.2.Laboratories
10.3.Others

11.Global Cancer Diagnostics Market, By Test Type (USD Million) 2021-203

11.1.Biopsy
- 11.1.1.Fine-needle Aspiration
- 11.1.2.Core Biopsy
- 11.1.3.Surgical Biopsy
- 11.1.4.Skin Biopsy /Punch Biopsy
- 11.1.5.Others
11.2.Others

12.Global Cancer Diagnostics Market, By Coverage (USD Million) 2021-2034

12.1.Public Insurance
12.2.Private Insurance

13.Global Cancer Diagnostics Market, (USD Million) 2021-2034

13.1.Global Cancer Diagnostics Market Size and Market Share

14.Global Cancer Diagnostics Market, By Region, (USD Million) 2021-2034

14.1.Asia-Pacific
- 14.1.1.Australia
- 14.1.2.China
- 14.1.3.India
- 14.1.4.Japan
- 14.1.5.South Korea
- 14.1.6.Rest of Asia-Pacific
14.2.Europe
- 14.2.1.France
- 14.2.2.Germany
- 14.2.3.Italy
- 14.2.4.Spain
- 14.2.5.United Kingdom
- 14.2.6.Rest of Europe
14.3.Middle East and Africa
- 14.3.1.Kingdom of Saudi Arabia
- 14.3.2.United Arab Emirates
- 14.3.3.Qatar
- 14.3.4.South Africa
- 14.3.5.Egypt
- 14.3.6.Morocco
- 14.3.7.Nigeria
- 14.3.8.Rest of Middle-East and Africa
14.4.North America
- 14.4.1.Canada
- 14.4.2.Mexico
- 14.4.3.United States
14.5.Latin America
- 14.5.1.Argentina
- 14.5.2.Brazil
- 14.5.3.Rest of Latin America

15.Company Profile

15.1.Abbott
- 15.1.1.Company details
- 15.1.2.Financial outlook
- 15.1.3.Product summary
- 15.1.4.Recent developments
15.2.BD
- 15.2.1.Company details
- 15.2.2.Financial outlook
- 15.2.3.Product summary
- 15.2.4.Recent developments
15.3.F. Hoffmann-La Roche Ltd
- 15.3.1.Company details
- 15.3.2.Financial outlook
- 15.3.3.Product summary
- 15.3.4.Recent developments
15.4.GE Healthcare
- 15.4.1.Company details
- 15.4.2.Financial outlook
- 15.4.3.Product summary
- 15.4.4.Recent developments
15.5.Hologic, Inc
- 15.5.1.Company details
- 15.5.2.Financial outlook
- 15.5.3.Product summary
- 15.5.4.Recent developments
15.6.Illumina, Inc
- 15.6.1.Company details
- 15.6.2.Financial outlook
- 15.6.3.Product summary
- 15.6.4.Recent developments
15.7.Koninklijke Philips N.V. (Philips)
- 15.7.1.Company details
- 15.7.2.Financial outlook
- 15.7.3.Product summary
- 15.7.4.Recent developments
15.8.QIAGEN
- 15.8.1.Company details
- 15.8.2.Financial outlook
- 15.8.3.Product summary
- 15.8.4.Recent developments
15.9.Siemens Healthcare GmbH
- 15.9.1.Company details
- 15.9.2.Financial outlook
- 15.9.3.Product summary
- 15.9.4.Recent developments
15.10.Thermo Fisher Scientific, Inc
- 15.10.1.Company details
- 15.10.2.Financial outlook
- 15.10.3.Product summary
- 15.10.4.Recent developments
15.11.Others